reviewNature Reviews Drug DiscoveryFeb 1, 2006Closed access

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,571
total citations
FWCI
26.31
Percentile
100%
References
101
Citations per year

Authors

6

Topics & keywords

Keywords
  • Pegaptanib
  • Aptamer
  • Macular degeneration
  • Vascular endothelial growth factor
  • Choroidal neovascularization
  • Medicine
  • Pharmacology
  • Neovascularization
No related works found for this paper.